Alice Zhang

MIT and Oxford‑trained Alice Zhang left her MD/PhD to found Verge Genomics, integrating single‑cell transcriptomics and graph neural networks to map disease‑age networks. Her lead compound VRG50635 for ALS entered Phase I with a fully in‑silico discovery pipeline, accelerating drug timelines for age‑related neurodegeneration. Zhang champions diversity in AI biotech and sits on Forbes 30‑Under‑30 alumni committees.